Ipsen reported global sales for Increlex of €17.3 million in 2023. INCRELEX ® (mecasermin) is indicated for the treatment of growth failure in pediatric patients aged 2 years and older with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback